Journal
JOURNAL OF CLINICAL NEUROSCIENCE
Volume 70, Issue -, Pages 198-201Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.jocn.2019.08.082
Keywords
hsa-miR-626; Parkinson's disease; Cerebrospinal fluid; Biomarker; microRNAs
Categories
Funding
- National Natural Science Foundation of China [81000542, 81200870, 30900469, 81430023, 81130021, 81361120404]
- Science and Technology Program of Hunan province [2014TT2014]
- SRFDP [20120162120079]
Ask authors/readers for more resources
microRNAs have been reported to suppress tumor growth, invasion, and metastasis and play roles in neurodegeneration disorders. Moreover, changes in microRNAs are found in the peripheral blood, cerebrospinal fluid (CSF), and brain tissues in patients of central nervous system diseases, including glioma, Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis and depression. Compared with other bodily fluids, CSF is the most accurate at representing the pathological processes of the brain. To understand whether microRNA expression may be dysregulated in the patients of PD, and to further discover potential diagnostic biomarkers and promising therapeutic targets for PD, we used real-time polymerase chain reaction (RT-PCR) to compare CSF microRNAs from 20 PD patients, 13 AD patients and 27 controls with other neurologic disorders such as encephalitis and Guillain-Barre syndrome. Finally, we found that the mean expression level of hsa-miR-626 was significantly reduced in the CSF of patients with PD compared with AD and controls. Our approach potentially identified a biomarker in CSF that upon further investigation, could be used for the detection, diagnosis, and monitoring of PD in combination with other PD biomarkers. (C) 2019 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available